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Abstract
Background: CD4+ T helper type 2 (TH2) cells, their cytokines IL-4, IL-5 and IL-13 and the transcription factor
STAT6 are known to regulate various features of asthma including lung inflammation, mucus production and
airway hyperreactivity and also drive alternative activation of macrophages (AAM). However, the precise roles
played by the IL-4/IL-13 receptors and STAT6 in inducing AAM protein expression and modulating specific features
of airway inflammation are still unclear. Since TH2 differentiation and activation plays a pivotal role in this disease,
we explored the possibility of developing an asthma model in mice using T cells that were differentiated in vivo.
Results: In this study, we monitored the activation and proliferation status of adoptively transferred allergen-
specific naïve or in vivo primed CD4+ T cells. We found that both the naïve and in vivo primed T cells expressed
similar levels of CD44 and IL-4. However, in vivo primed T cells underwent reduced proliferation in a lymphopenic
environment when compared to naïve T cells. We then used these in vivo generated effector T cells in an asthma
model. Although there was reduced inflammation in mice lacking IL-4Ra or STAT6, significant amounts of
eosinophils were still present in the BAL and lung tissue. Moreover, specific AAM proteins YM1 and FIZZ1 were
expressed by epithelial cells, while macrophages expressed only YM1 in RAG2
-/- mice. We further show that FIZZ1
and YM1 protein expression in the lung was completely dependent on signaling through the IL-4Ra and STAT6.
Consistent with the enhanced inflammation and AAM protein expression, there was a significant increase in
collagen deposition and smooth muscle thickening in RAG2
-/- mice compared to mice deficient in IL-4Ra or STAT6.
Conclusions: These results establish that transfer of in vivo primed CD4+ T cells can induce allergic lung
inflammation. Furthermore, while IL-4/IL-13 signaling through IL-4Ra and STAT6 is essential for AAM protein
expression, lung inflammation and eosinophilia are only partially dependent on this pathway. Further studies are
required to identify other proteins and signaling pathways involved in airway inflammation.
Background
CD4+ T helper type 2 (TH2) cytokines such as IL-4, IL-
5 and IL-13 play a critical role in inducing allergy and
asthma. These cytokines act on multiple cells types to
initiate and propagate the hallmark features of asthma
such as pulmonary inflammation, periodic narrowing of
airways and mucus hypersecretion [1-7]. Experiments
with mice deficient in these cytokines and studies in
asthma patients have confirmed these findings [8-10].
Also, the fact that TH2 cells are required in this disease
setting has been demonstrated by using IL-4
-/- mice and
adoptive transfer studies [3,6,8,11]. Apart from TH2
cells, IL-4 and IL-13 are also secreted by natural killer
(NK) T cells, basophils, mast cells, macrophages and
activated eosinophils (reviewed in [12]).
IL-4 and IL-13 share receptor chains and signaling
proteins. Binding of either cytokine to the Type I or
Type II receptor complex leads to the phosphorylation
of signal transducer and activator of transcription factor
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genes have been linked to increased risk of asthma
[15,16]. There is ample evidence that IL-4 signaling
through IL-4Ra and STAT6 is important for TH2 differ-
entiation and for IgE class-switching in B cells [13,14].
Furthermore, mucus hypersecretion, goblet cell hyper-
plasia and airway hyperresponsiveness (AHR) were com-
pletely abolished in IL-4Ra
-/- or STAT6
-/- mice [1,4,17].
We have previously shown that apart from TH2 cells,
IL-4Ra expression on a population of CD11b+ cells
contributed to the severity of lung inflammation and
eosinophil recruitment [7]. Although these signaling
molecules have been studied extensively, there are con-
flicting reports in the literature regarding the roles of
IL-4Ra and STAT6 in modulating specific features of
airway inflammation. Some studies have shown that
there was no eosinophil recruitment in STAT6
-/- mice
[6], while other groups including us contend that lung
eosinophilia and inflammation are only partially depen-
dent on STAT6 [1,18].
Recently it has been established that IL-4 and IL-13 can
promote differentiation of alternatively activated macro-
phages (AAM) (reviewed in [19,20]). During Type II
inflammation, AAMs as well as epithelial cells produce
certain characteristic factors such as Arginase 1, chitinase-
like mammalian proteins (eg. YM1) and found in inflam-
matory zone (FIZZ; also named as Resistin- like molecule,
RELM) proteins. Four different sub-types of FIZZ proteins
have been reported in the literature- FIZZ1-4. FIZZ1 was
originally discovered in the bronchoalveolar lavage (BAL)
fluid in a mouse model of asthma [21]. Elevated levels of
FIZZ1 and YM1 mRNA or protein have since been
detected in parasite infection models [20,22], allergic lung
inflammation [21,23,24], allergic peritonitis [24], bleomy-
cin-induced lung fibrosis [25] and hypoxia-induced pul-
monary hypertension [26]. Interestingly, the promoter
regions of both FIZZ1 and YM1 have functional binding
sites for STAT6 [23,24], which explains how IL-4 and IL-
13 can induce expression of these proteins. Our group has
shown previously using in vitro studies, that FIZZ1, YM1
and Arginase 1 mRNA are preferentially upregulated by
IL-4 and to a lesser extent by IL-13 [27]. Loss of STAT6
signaling results in a significant reduction in FIZZ1 and
YM1 mRNA levels in different model systems [24,25].
However, the effect of IL-4Ra or STAT6 on FIZZ1/YM1
protein induction in an asthma model has not yet been
studied.
It is well established that signaling through the IL-4
pathway is important for TH2 cell differentiation and
cytokine production (reviewed in [28]). IL-4 signaling
through the IL-4R/STAT6 axis upregulates GATA3, the
TH2 master transcription factor. Adoptive transfer of
wild type TH2 cells into mice is an effective tool to bypass
the role of STAT6 and IL-4Ra in TH2 cell differentiation,
while allowing the study of these signaling molecules in
the effector phase of asthma. Most groups use in vitro-
generated TH2 effectors for this purpose. However, this
protocol involves several rounds of in vitro priming and
expansion using large quantities of IL-4. Also, it is
becoming evident that in vivo TH2 differentiation is more
complex and that certain signals may be missing when
cells are differentiated in vitro (reviewed in [29]). It is
now known that TSLP, IL-25 and IL-1 family cytokines
can be involved in induction or maintenance of the TH2
phenotype [29]. In order to avoid using in vitro Tc e l l
activation, we isolated Ovalbumin (OVA)-specific CD4+
T cells from either unimmunized DO11.10xRAG2
-/- mice
to get naïve CD4+ T cells or DO11.10xRAG2
-/- mice
immunized with OVA/Alum to get in vivo-primed CD4+
T cells. Previous dogma led to the assumption that it
would be difficult to immunize TCR transgenic mice
[30,31] as T cells in these mice undergo reduced prolif-
eration. However, recent reports indicate that it is possi-
ble to immunize TCR transgenic mice and that T cell
proliferation and cytokine production are independent of
each other [32,33].
In this study, we found that in vivo primed CD4+ T
cells underwent reduced proliferation in a lymphopenic
environment when compared to naïve CD4+ T cells.
Using this modified asthma model with in vivo generated
effector T cells, we demonstrate that although there was
a reduction in recruitment of inflammatory cells and
eosinophils in absence of IL-4Ra or STAT6, significant
amounts of eosinophils were still present both in the
BAL and also the lung tissue of STAT6xRAG2
-/- and IL-
4RaxRAG2
-/- mice. Interestingly, YM1 protein was
expressed by both epithelial cells and macrophages, while
FIZZ1 protein was only expressed by epithelial cells in
RAG2
-/- mice. We further show that FIZZ1 and YM1
protein expression in the lung was completely dependent
on signaling through the IL-4Ra and STAT6. Thus it
appears that while IL-4/IL-13 signaling through IL-4Ra
and STAT6 is essential for induction of AAM genes,
lung inflammation and eosinophilia are only partially
dependent on this pathway.
Results
Activation and proliferation status of naïve versus in vivo
primed T cells
Since it has been suggested that TH2 differentiation in vivo
is quite complex [29] and cannot necessarily be mimicked
by in vitro priming of T cells, we tested the possibility of
using either naïve or in vivo primed CD4+ DO11.10+ T
cells. First, we determined if the in vivo primed T cells
were capable of secreting more TH2 cytokines as a result
of OVA/Alum immunization of D011.10xRAG2
-/- mice.
Splenocytes isolated from either unimmunized (naïve) or
immunized D011.10xRAG2
-/- mice were stimulated with
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culture supernatant was measured by ELISA. We found
that, just one round of priming with OVA/Alum was suffi-
cient to induce robust secretion of TH2 cytokines, IL-4
and IL-5 (Figure 1). The amount of IL-4 and IL-5 pro-
duced by cells isolated from immunized mice (14.2 ng/ml
and 4.67 ng/ml respectively) was significantly higher than
that of naïve cells (0.17 ng/ml and 0.07 ng/ml).
Next we compared the ability of the naïve and in vivo
primed CD4+ T cells to be activated upon OVA/Alum
priming. Since differentiation of CD4+ T cells can often
be accompanied by cell proliferation, we also monitored
T cell proliferation using 5-bromo-2-deoxyuridine
(BrdU) incorporation. In order to test this, we trans-
ferred naïve or in vivo primed T cells into STAT6x-
RAG2
-/- mice by tail vein injection, followed by
immunization with OVA/Alum using a protocol shown
in Figure 2A. One group of mice was injected with
BrdU. Splenocytes were harvested on day 5 and analyzed
by flow cytometry. We found that although the total
number of splenocytes isolated from these two groups
was similar (22.75 × 10
6 and 23 × 10
6 cells respectively;
Table 1), the number of DO11.10+ CD4+ T cells in the
in vivo primed transfer group was double that of the
naïve transfer group- 4.5% vs. 2.29% (Figure 2B); 587
cells vs. 267 cells (Table 1). However the percentage of
naïve DO11.10+ CD4+ T cells that were proliferating, as
measured by BrdU incorporation was higher when com-
pared to the in vivo primed DO11.10+ CD4+ T cells-
22% vs. 10% (Table 1). We also looked at cell surface
activation markers such as CD44 (hyaluronic acid recep-
tor) expressed by these cells. The majority of cells in
both groups on day 5 were CD44hi, although expression
of this protein was slightly higher in the group receiving
in vivo primed T cells (Figure 2B and Table 1). Interest-
ingly, although only 10% of the CD4+ T cells in the
primed T cell transfer group and 22% of these cells in
the naïve T cell transfer group were BrdU+, CD44hi
expression by these cells in the two groups of mice was
97% and 82% respectively. This suggests that even cells
that did not divide in both groups were expressing high
levels of CD44 and were activated.
Another set of STAT6xRAG2
-/- mice that received
either naïve or in vivo primed DO11.10 T cells were
immunized twice with OVA/Alum within a span of 1
week (Figure 2A; similar to the antigen sensitization
protocol used in the allergic lung inflammation experi-
ments). The activation status of the adoptively trans-
ferred T cells and the amount of IL-4 produced by these
cells was monitored. The number of spleen cells recov-
ered at this stage (day 12) from the naïve T cell transfer
group was twice as much as the number recovered from
spleens of mice that had received in vivo primed T cells
(Table 2). Moreover, the percentages of naïve DO11.10+
CD4+ T cells (12.7%) in the spleen were also higher
when compared to that of the in vivo primed DO11.10+
CD4+ T cells (5.11%; Figure 2b). This result correlates
well with the BrdU incorporation data and indicates
that naïve DO11.10+ CD4+ T cells proliferate more in a
lymphopenic environment, which leads to greater accu-
mulation of these cells in spleens of mice at a later time.
This accumulation of T cells may be due to homeostatic
proliferation. However, the percentage of cells expres-
sing CD44 (> 99%) and IL-4 (18.8% and 19.8%) was
similar in both the naïve and in vivo primed groups on
day 12 (Table 2 and Figure 2C).
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Figure 1 Cytokine production by unimmunized and OVA/Alum immunized D011.10xRAG2
-/- mice. Splenocytes isolated from either naïve
(unimmunized) or OVA/Alum immunized D011.10xRAG2
-/- mice were cultured in media containing 20 U/ml IL-2 and were either stimulated with
PMA/Ionomycin (PMA/Ion) or left untreated for 18 h. IL-4 and IL-5 secretion into the cell culture supernatant was quantitated using ELISA. Data
represented as concentration of cytokine ± SEM in ng/ml. n = 3 for each group. * p < 0.05.
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Figure 2 Comparison of proliferation and activation status of naïve vs. in vivo primed T cells. (A) Schematic representation of the
protocol used in this experiment. Briefly, 1.5 × 10
6 naïve or in vivo primed CD4+ T cells were adoptively transferred into STAT6xRAG2
-/- mice
and primed with OVA/alum i.p. on day 1. One group of mice was treated daily with BrdU (1 mg/mouse) i.p for 3 days before harvesting spleens
on day 5. Splenocytes were pooled together and total cell counts were recorded. Cells were stained with anitbodies to CD4, KJ126, CD44 and
BrdU and flow cytometry was performed. Another group of mice, that didn’t receive BrdU were immunized with OVA/alum a second time on
day 8. Four days later, splenocytes were harvested, counted and stimulated with PMA (50 ng/ml) and Ionomycin (1 μg/ml) for 6 h. (B) BrdU and
CD44 expression in the CD4+ KJ126+ population in the naïve T cell or in vivo primed T cell transfer groups are shown. (C) CD44 expression in
the CD4+ KJ126+ population in naïve vs. in vivo primed T cell transfer groups on day 12 is shown. IL-4 production by naïve and in vivo primed
DO11.10 CD4 T cells was measured by intracellular cytokine staining (ICS).
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eosinophilia and mucus production
Considering that naïve DO11.10+ CD4+ T cells were
proliferating more in a lymphopenic environment and
s i n c ew ew a n t e dt of o c u so nt h ee f f e c t o rf u n c t i o n so f
IL-4 and IL-13 but not their role in priming naïve
T cells, we chose the in vivo primed DO11.10+ CD4+ T
cells for all further experiments.
Several groups including ours have shown that IL-4
and IL-13 signaling through IL-4Ra and STAT6 plays an
important role in inducing and exacerbating eosinophilic
inflammation and mucus production in the lungs
[1,5-7,16,18]. Since some of these studies were conducted
using in vitro generated TH2 effectors, we examined
whether similar responses would be observed using in
vivo primed T cells. Furthermore, although similar stu-
dies have been conducted with STAT6
-/- mice or IL-
4Ra
-/- mice alone [1,6,7], no head to head comparisons
between mice deficient in STAT6 or IL-4Ra have been
made. To tease out the precise roles played by these sig-
naling molecules, we conducted allergic inflammation
studies on RAG2
-/-, STAT6xRAG2
-/- and IL-4Rax-
RAG2
-/- mice using our model of transferring in vivo
primed T cells (Figure 3A).
The degree of airway inflammation, eosinophil recruit-
ment and mucus production in the lungs was analyzed in
the three groups of mice. As reported earlier [1,7], priming
with alum alone did not induce eosinophilia and airway
inflammation (Figure 3B) and served as a negative control.
Upon enumerating the cellular composition in the BAL,
w ef o u n dt h a tt h et o t a ln u m b e ro fc e l l sr e c o v e r e df r o m
OVA treated RAG2
-/- mice was significantly higher (2.1 ×
10
6 cells) than the number of cells recovered from OVA
treated STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice (1.26
×1 0
6 and 0.9 × 10
6 cells respectively). (Figure 3B). Among
the different cell types (macrophages, eosinophils, lympho-
cytes and neutrophils) found in the BAL, a 2-3 fold reduc-
tion in the numbers and percentages of eosinophils was
seen in STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice when
compared to RAG2
-/- mice challenged with OVA (Figure
3B and additional file 1, Figure S1A). In each case, the
numbers of eosinophils, macrophages and lymphocytes
present in the OVA treated mice were much greater than
the alum treated mice (Figure 3B).
H&E stained lung sections of OVA treated RAG2
-/-
mice demonstrated severe lung inflammation (Additional
file 1, Figure S1B, panel a) and most of the cellular infil-
trate was composed of eosinophils (Additional file 1,
Figure S1B, panel b). Multinucleated giant cells (MNGs)
were also present in large numbers. In contrast, in
absence of STAT6 and IL-4Ra only minor cuffing of the
airways and blood vessels was observed (Additional file 1,
Figure S1B, panels d & g respectively). Eosinophil recruit-
ment into the lung although reduced, was not completely
abolished in STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice
(Additional file 1, Figure S1B, panels e & h respectively).
PAS staining on the above lung sections indicated that
mucus production by epithelial cells was fully dependent
on STAT6 and IL-4Ra (Additional file 1, Figure S1B,
panels c, f and i). This is not surprising as it known that
mucus production is mainly driven by IL-13 mediated
STAT6 activation [4,5,34].
Table 1 Comparison of cells present in mice receiving naïve or in vivo primed CD4+DO11
Total Splenocytes # of CD4+ DO11.10+
lymphocytes
% BrdU+ % CD44+
STAT6xRAG2 + primed CD4 T cells 23 × 10
6 cells 587 cells 10% 96.9%
STAT6xRAG2 + Naïve CD4 T cells 22.75 × 10
6 cells 267 cells 22% 82%
Cell proliferation studies were conducted using the protocol mentioned in Figure 2 and materials and methods. Briefly, naïve or in vivo primed CD4+ T cells were
adoptively transferred into STAT6xRAG2
-/- mice on day 0, followed by OVA/alum immunization of day 1. Mice were treated with BrdU i.p for 3 days. On day 5,
splenocytes were harvested, single cell suspensions were prepared and total cell numbers were counted (column 1). Cells were stained with fluorochrome
conjugated antibodies and analyzed by flow cytometry. Lymphocytes were gated based on forward and side scatter parameters. The CD4+ DO11.10+ population
in each transfer group was gated based on double expression of CD4 and KJ126 by each cell (column 2). BrdU and CD44 expression in these gated cells was
examined (columns 3 and 4 respectively). The numbers/percentages in columns 2-4 were determined by FACS Analysis. 20,000 events (splenocytes) were
collected for each tube/analyte.
Table 2 Comparison of cells present in mice receiving naïve or in vivo primed CD4+DO11
Total Splenocytes # of CD4+ DO11.10+
lymphocytes
% CD44+
STAT6xRAG2 + primed CD4 T cells 157 × 10
6 cells 328 cells 99.3%
STAT6xRAG2 + Naïve CD4 T cells 350 × 10
6 cells 629 cells 99.5%
T cell activation studies were conducted using the protocol mentioned in Figure 2 and materials and methods. Briefly, naïve or in vivo primed CD4+ T cells were
adoptively transferred into STAT6xRAG2
-/- mice on day 0, followed by OVA/alum immunization of days 1 and 8. Four days later, splenocytes were harvested,
single cell suspensions were prepared and cells were counted (column 1). Splenocytes were stimulated with PMA and Ionomycin for 6 h, followed by FACS
staining and analysis. Lymphocytes were gated based on forward and side scatter parameters. The CD4+ DO11.10+ population in each transfer group was gated
based on double expression of CD4 and KJ126 by each cell (column 2). CD44 expression in these gated cells was examined (column 3). The numbers/
percentages in columns 2 and 3 were determined by FACS Analysis. 20,000 events (splenocytes) were collected for each tube/analyte.
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Figure 3 Degree of BAL eosinopilia, cytokine and chemokine secretion in RAG2
-/- STAT6xRAG2
-/- or IL-4RaxRAG2
-/- mice.T h ea s t h m a
protocol used in this study is depicted in (A). In vivo primed DO11.10+ CD4+ T cells were adoptively transferred into RAG2
-/-, STAT6xRAG2
-/- or
IL-4RaxRAG2
-/- mice. Mice were primed with either alum or 100 μg of Ova in alum i.p on d. 1 & 6 and then challenged with nebulized PBS or
1% Ova in PBS on d. 12 &14. BAL fluid was recovered 48 h after the last challenge and cells were analyzed by differential staining. Lung tissue
was collected for histological analysis. (B) The total number of cells (T), macrophages (M), eosinophils (E), lymphocytes (L) and
polymorphoneutrophils (P) present in the BAL in RAG2
-/-, STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice are represented here in the form of bar graphs.
Data represented as numbers ± SEM. * (p < 0.05), represents statistically significant differences between the OVA and Alum treated mice in each
group. n = 5 for Ova treated mice, n = 3 for alum treated. (C) Chemokine and cytokine levels in BAL samples from OVA primed and challenged
RAG2
-/-, STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice were analyzed using a multiplex array system. Data are presented as mean chemokine or
cytokine level in pg/ml ± SEM. * p < 0.05; ** p < 0.01; + p < 0.0001. n = 4 for RAG2
-/- mice, n = 3 each for STAT6xRAG2
-/- or IL-4RaxRAG2
-/-
mice. Representative data from one of three independent experiments is shown.
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3B) in the three mouse strains were recapitulated in the
lung tissue. The number of eosinophils recruited to the
airways and blood vessels in OVA primed and challenged
STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice was signifi-
cantly reduced but not completely absent (Additional file
2, Figure S2A & B). A corresponding increase in mono-
nuclear cell infiltration was observed in these mice. Sur-
prisingly, the number of mononuclear cells in STAT6
deficient mice was higher than in IL-4Ra deficient mice. It
is possible that this is linked to the presence of increased
numbers of myeloid progenitor cells that have been
reported in STAT6
-/- mice [35]. However, we found signif-
icantly higher eosinophils in the lung parenchyma in
STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice, when com-
pared to RAG2
-/- mice (Additional file 2, Figure S2C).
Taken together, these results suggest that in vivo primed
CD4+ T cells can induce robust allergic lung inflammation
in mice. In this model, STAT6 and IL-4Ra expression are
only partially required for inducing pulmonary inflamma-
tion and eosinophilia.
Chemokine and cytokine profile in the BAL in presence or
absence of STAT6 and IL-4Ra
IL-4 and IL-13 signaling can induce production of many
chemokines by different cell types. Eotaxin-1 (CCL11)
and Eotaxin-2 (CCL24) are eosinophil chemoattractive
proteins that are predominantly produced by epithelial
cells in mice (reviewed in [36]), upon IL-4 or IL-13 sti-
mulation [37,38]. Previous studies have shown that
induction of eotaxin, eotaxin 2 and TARC mRNA in the
lungs of OVA-challenged mice was STAT6 dependent
[6,37]. We determined the quantities of eotaxin, TARC
and mouse JE/CCL2 secreted into the BAL (Figure 3B,
panel b). Using our model of in vivo primed T cell trans-
fer and OVA-induced allergic lung inflammation, we
further show that significantly elevated levels of eotaxin
and TARC protein were found in RAG2
-/- mice when
c o m p a r e dh e a dt oh e a dw i t hS T A T 6 x R A G 2
-/- and IL-
4RaxRAG2
-/- mice. A similar trend is seen in the case of
JE/CCL2 production. Since eotaxin plays an important
role in eosinophil trafficking, the reduced amount of
eotaxin found in the BAL of STAT6xRAG2
-/- and IL-
4RaxRAG2
-/- mice could explain the lower numbers of
eosinophils present around the airways in mice (Figures
3B and S2).
As TH2 cytokines have been implicated in allergic lung
inflammation, we evaluated IL-4, IL-5 and IL-13 secre-
tion into the lungs and analyzed the contribution of
STAT6 and IL-4Ra head to head in this process, using
our in vivo primed T cell model. Since we provided WT
OVA-specific T cells to all three groups of mice, these
cells would be able to produce TH2 cytokines. We found
that upon priming and challenge with OVA, both
RAG2
-/- and STAT6xRAG2
-/- mice secreted similar
amounts of IL-4 and IL-13 into the BAL (Figure 3C, bot-
tom left). However, significantly higher levels of IL-4
were present in the BAL of IL-4RaxRAG2
-/- mice when
compared to the other two groups (Figure 3C). Although
not significant, IL-13 secreti o ni nt h e s em i c ef o l l o w e da
similar trend. It is published that binding of IL-4 to the
IL-4R complex induces internalization and uptake of the
cytokine [39]. Thus, in mice deficient in IL-4Ra,a b s e n c e
of the IL-4R on cell surfaces may be preventing the inter-
nalization of IL-4 and IL-13, thus increasing the concen-
tration of these cytokines in the BAL. Similar results
were obtained by other groups when antibodies against
the IL-4Ra chain or IL-13Ra1 were used [34,40].
In case of IL-5, increasing amounts of this cytokine was
detected in the three mouse strains, with the lowest quan-
tity of IL-5 present in the BAL of RAG2
-/- mice, inter-
mediate levels in STAT6xRAG2
-/- mice and the highest in
IL-4RaxRAG2
-/- mice (Figure 3C, bottom right). Studies
have shown that when in vitro generated TH2 effectors
were adoptively transferred into STAT6
-/- mice, there was
a dramatic increase in IL-5 secretion in the BAL [6]. The
authors speculated that this difference was due to
decreased consumption of IL-5 by eosinophils. In our
model also, we find that there is a correlation between the
degree of eosinophilic inflammation in mice and the
amount of IL-5 present in the BAL. Thus the lower levels
of IL-5 found in the BAL fluid in RAG2
-/- mice may be
explained by increased consumption of this cytokine by
eosinophils recruited into the lungs (seen in Figure 3B and
additional file 2 Figure S2).
Migration of TH2 cells into the lungs is independent of
STAT6 expression
Previous studies have shown that STAT6 expression was
necessary for TH2 cell trafficking into the lung upon
inhalation of Ovalbumin. Mathew et. al. reported that in
the absence of STAT6, less antigen specific TH2 cells
migrated into the lungs [6]. To check if this was true in
our studies, lung sections were stained with antibodies
to CD3 to identify T cells. Since all mice were on a
RAG deficient background, the only CD3+ T cells pre-
sent in the lungs were the OVA-specific T cells that we
adoptively transferred. As evident from Figure 4A,
absence of STAT6 or IL-4Ra did not block migration of
antigen specific T cells into the lungs of mice. When
the CD3+ cells in these mice were quantified, we found
that significantly greater numbers of T cells were
recruited in the lungs of IL-4RaxRAG2
-/- mice when
compared to RAG2
-/- mice and a similar trend was seen
in STAT6xRAG2
-/- (Figure 4B). Thus when the T cells
express STAT6 or IL-4Ra themselves, deficiency of
those proteins in lung resident cells does not affect T
cell trafficking.
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expression
Liu et. al reported that induction of FIZZ1 transcripts
was STAT6 dependent in a bleomycin-induced lung
fibrosis model [25]. YM1 mRNA was also upregulated
in a STAT6 dependent manner in a mouse model of
allergic peritonitis [24]. However, the expression pat-
terns of these AAM proteins by epithelial cells and
macrophages have not been studied in allergic lung
inflammation. Moreover, we have observed a disconnect
between the amounts FIZZ1 mRNA and protein
induced by IL-4 stimulated macrophages in vitro [27].
Thus, we examined the expression profile of FIZZ1 and
YM1 protein in our model and investigated the role of
STAT6 and IL-4Ra in upregulation of these proteins.
Serial lung sections from OVA sensitized and challenged
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Figure 4 CD3+ T cells migrate into the lung in absence of STAT6. Allergic lung disease was induced in RAG2
-/-, STAT6xRAG2
-/- or IL-
4RaxRAG2
-/- mice as described above. Images (10×, 40× and 100× magnifications) of representative lung sections stained with antibodies to
CD3 are shown in (A). CD3+ cells appear brown. Panels a-c: RAG2
-/- lung sections; d-f: STAT6xRAG2
-/- sections and g-i: IL-4RaxRAG2
-/- sections. n
= 5 for each mouse strain. (B) Graphical representation of the immunohistochemistry data shown above. Number of CD3+ cells in each lung
section was counted and graphed. Data represented as cell counts ± SEM. HPF: high power field; 100×. * p < 0.05.
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-/-,S T A T 6 x R A G 2
-/- and IL-4RaxRAG2
-/- mice
were stained with antibodies against both YM1 and
FIZZ1 by immunohistochemistry (Figure 5A). Lung
epithelial cells in RAG2
-/- mice stained strongly for
FIZZ1 (Figure 5A, panel a & b) and YM1 (panel c & d).
However, macrophages from these mice were positive
for only YM1 but not FIZZ1 (Figure 5B, panel a & b).
Multinucleated giant cells present in the lungs of
RAG2
-/- mice also expressed YM1 (Figure 5C). In com-
parison, no FIZZ1 or YM1 protein was produced by
epithelial cells (Figure 5A, panel e-h and i-l) or macro-
phages (Figure 5B, panel c, d and e, f) in mice deficient
in IL-4Ra or STAT6.
To quantify the amount of FIZZ1 and YM1 protein that
was produced by each mouse strain, we analyzed the
expression pattern of these proteins secreted into BAL
fluid by western blotting. Total protein present in the BAL
fluid samples from RAG2
-/-, STAT6xRAG2
-/- and IL-
4RaxRAG2
-/- mice was first quantitated; more total pro-
tein was recovered from RAG2
-/- BAL when compared to
mice lacking STAT6 or IL-4Ra (data not shown). Gener-
ally, the amount of total protein present in BAL correlates
with the degree of inflammation seen in mice. In order to
compare the quantities of FIZZ1 and YM1 present in the
different mouse strains, equal amounts of total BAL pro-
tein from RAG2
-/-, STAT6xRAG2
-/- and IL-4RaxRAG2
-/-
mice were used. The BAL protein samples were resolved
by polyacrylamide gel electrophoresis, transferred onto a
membrane and probed with antibodies to YM1 or FIZZ1.
Similar to the immunohistochemistry study, large amounts
of FIZZ1 and YM1 were secreted into the BAL in RAG2
-/-
mice, but this was greatly reduced in the absence of
STAT6 and IL-4Ra (Figure 6A). Densitometry analysis of
the blots revealed that the differences seen were significant
(Figure 6B). These results demonstrate that STAT6 activa-
tion through IL-4Ra signaling is required for expression of
FIZZ1 protein in lung epithelial cells and YM1 protein in
macrophages and epithelial cells during allergic lung
inflammation.
Effect of STAT6 and IL-4Ra on airway remodeling
One characteristic feature of asthma is airway remodeling,
which involves an increase in airway smooth muscle mass
and enhanced collagen deposition. It has been reported
that both eosinophils and AAM products such as FIZZ1
and YM1 can cause lung fibrosis and smooth muscle
thickening [26,41-44]. Thus, we analyzed the amount of
collagen deposition and airway smooth muscle thickness
in RAG2
-/-,S T A T 6 x R A G 2
-/- and IL-4RaxRAG2
-/- mice.
Masson’s Trichrome staining of representative lung sec-
tions from each mouse strain revealed that greater quanti-
t i e so fc o l l a g e n( s h o w ni nb l u e )w a sp r e s e n ta r o u n dt h e
airways (Figure 7A, panel a) and blood vessels (panel d) in
RAG2
-/- mice, when compared with mice lacking STAT6
and IL-4Ra (Figure 7A, panels b&c, e&f). Quantification
of the collagen staining using image analysis software
showed that the differences were significant (Figure 7B).
Furthermore, the thickness of the smooth muscle layer
around the airways (the transverse diameter) was also sig-
nificantly reduced in absence of STAT6 and IL-4Ra (Fig-
ure 7A and 7C). The airway smooth muscle layer was
identified by H&E staining of lung sections (Figure 7A,
panels g-i) and the diameter of the muscle layer was mea-
sured at three different points in each airway examined,
using Image J software [45,46] (Figure 7C).
Discussion
Although research on the cytokines IL-4 and IL-13 over
the past decade has substantially increased our under-
standing of their contribution to the pathophysiology of
asthma, the extent to which the signaling pathways they
activate play a role in airway inflammation and alternative
activation of macrophages have not yet been determined.
In this study, we used STAT6 and IL-4Ra deficient mice
on a RAG2
-/- background to examine the role of the IL-4/
IL-13 pathway in inducing the aforementioned features of
allergic lung disease. Since TH2 cells are indispensable in
this disease setting, we provided T cells exogenously. Pre-
viously, most groups used in vitro generated TH2 effectors
for this purpose [6,7]. Here, we developed a model
wherein in vivo primed ovalbumin-specific CD4+ T cells
were adoptively transferred into various recipient mice,
followed by immunization and challenge with OVA. We
examined whether naïve CD4+ T cells or in vivo primed
CD4+ T cells isolated from DO11.10x RAG2
-/- would be
more suitable for this asthma model. We found that in
vivo primed T cells proliferated less when compared to
naïve T cells as suggested by the following results: i. lower
levels of BrdU incorporation in cells; ii. the number of
CD4+DO11.10+ cells recovered from lymphopenic mice
was half of that recovered from the naïve T cell transfer
group. This increased proliferation seen in the naïve T cell
transfer group may be due to homeostatic proliferation. It
has been demonstrated, that naïve T cells from TCR trans-
genic mice undergo slow homeostatic proliferation in lym-
phopenic mice, which is dependent on IL-7 [47,48].
It has been proposed that entry into the cell cycle (i.e.
cell proliferation) and clonal expansion is necessary for
T cell differentiation [30,31,49]. Also, several groups have
shown that TCR transgenic mice that have high frequency
of antigen-specific T cells show only weak proliferation
upon TCR ligation and that the T cells become anergic or
die of apoptosis [50,51]. However, a study conducted by
Laouar et. al. [32] and our studies have shown that when
T cells from TCR transgenic mice were activated in vivo
with specific peptide/antigen, these cells express cell sur-
face activation markers such as CD44 and secrete effector
cytokines, in spite of proliferating less (BrdU
- cells were
Dasgupta et al. BMC Immunology 2011, 12:60
http://www.biomedcentral.com/1471-2172/12/60
Page 9 of 18expressing high levels of CD44). Why these transgenic T
cells showed reduced proliferation is not known exactly,
b u ti ti sh y p o t h e s i z e dt h a ta th i g hc e l lf r e q u e n c y ,t h e r e
may be increased competition for growth factors, limited
access to peptide/MHC complexes and also limited lym-
phoid space for expansion. The other difference between
10X, FIZZ1 40X, FIZZ1 10X, YM1 40X, YM1
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Figure 5 FIZZ1 and YM1 expression in the lung is dependent on STAT6 and IL-4Ra. Allergic lung inflammation was induced in RAG2
-/-,
STAT6xRAG2
-/- or IL-4RaxRAG2
-/- mice as mentioned in Figure 3 and materials and methods. FIZZ1 and YM1 expression was analyzed in serial
sections of mouse lungs by immunohistochemistry. Photomicrographs of FIZZ1 and YM1 expression in epithelial cells (A) and macrophages (B)
in representative lung sections are shown. (C) YM1 expression in multinucleate giant cells (MNG) in RAG2
-/- mice. Images in (B) and (C) are of
100× magnification.
Dasgupta et al. BMC Immunology 2011, 12:60
http://www.biomedcentral.com/1471-2172/12/60
Page 10 of 18our study and the ones where transgenic T cells became
anergic/apoptotic is the method of immunization: we used
ovalbumin complexed with an adjuvant (alum) instead of
using the antigen alone as was done previously. Thus, our
results clearly show that in vivo primed CD4+ T cells from
DO11.10 transgenic mice can be used to induce the hall-
mark features of asthma in mice. This effect is not
restricted to one transgenic mouse strain; similar results
were obtained when OT-II mice were used (data not
shown).
In mice that lack STAT6 or IL-4Ra,T H2 cell differen-
tiation is impaired but they have normal TH1 cell differ-
entiation. In order to track the exogenous in vivo primed
T cells that we were transferring into these mice and to
prevent interference of TH1 cells, we used STAT6 or IL-
4Ra deficient mice on a RAG2
-/- background for our
asthma experiments. RAG2
-/- mice were used as controls.
In this study, we tested the ability of in vivo primed CD4
+ T cells as opposed to in vitro generated TH2 effectors
to support allergic lung inflammation. We found that in
the absence of STAT6 and IL-4Ra, mice developed less
pulmonary inflammation, reduced perivascular and peri-
bronchial cuffing and decreased eosinophilia than our
control mice. Mucus production in these mice was abro-
gated. This was expected since it has been conclusively
shown that mucus production is dependent on STAT6
activation by IL-13 signaling [4,5,34]. However, both
STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice that were
primed and challenged with OVA were able to recruit
significantly higher numbers of eosinophils when com-
pared to alum primed mice. Several studies have shown
the importance of these signaling molecules in asthma,
but the roles of IL-4Ra and STAT6 in modulating speci-
f i cf e a t u r e so fa i r w a yi n f l a mmation were unclear. Here
we show that STAT6 and IL-4Ra a r eo n l yp a r t i a l l y
required for eosinophil recruitment to the lung. Our data
matches with what was observed by Kuperman et. al.[ 1 ]
but is in apparent contradiction to that shown by
Mathew et. al. [6]. Furthermore, in contrast to the latter’s
finding, we observe that there is no defect in T cell
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Figure 6 Presence of FIZZ1 and YM1 protein in BAL fluid. BAL fluid samples from RAG2
-/-, STAT6xRAG2
-/- or IL-4RaxRAG2
-/- mice treated as
described in Figure 4 were collected. FIZZ1 and YM1 protein secreted into the BAL fluid in the three groups of mice was detected by western
blotting (A). Equal amounts of total protein were loaded into every well. Each lane represents an individual mouse. Densitometry analysis was
performed on the autoradiograms from each blot and the values are represented on a graph (B). White bars represent densitometry values for
FIZZ1, black bars represent YM1. * p < 0.01; # p < 0.001. n = 3 for each group.
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4Ra. Differences in the experimental set up may explain
these discrepancies: we and Kuperman et. al.u s e dt w o
priming steps with OVA/Alum in the asthma protocol,
which was omitted by the other group. Recently it was
demonstrated that alum stimulates the innate immune
system by activating the Nalp3 inflammasome, leading to
secretion of pro-inflammatory cytokines such as IL-1b,
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Figure 7 Reduced airway remodeling in mice deficient in STAT6 and IL-4Ra. RAG2
-/-, STAT6xRAG2
-/- or IL-4RaxRAG2
-/- mice were subjected
to the asthma protocol described in Figure 3. (A) Paraffin embedded lung sections from each group of mice were stained with Masson’s
Trichrome. Keratin and muscle fibers are stained in red, collagen in blue, cytoplasm in light red/pink and nuclei in black. Photomicrographs of
collagen deposition around the airways (panels a-c) or blood vessels (panels d-f) were collected at 10× (panels a-f) and 100× (inset)
magnification. Photomicrographs (100×) of the airway smooth muscle (ASM) layer in H&E stained lung sections from each mouse group is
shown in panels g-i. Arrows depict the thickness of the ASM layer (transverse section). (B) The amount of collagen present in the lung was
quantified using NIH Image J software. Data is represented as area of collagen (blue stain) ± SEM. # p < 0.001. n = 20 airways/blood vessels per
group. (C) The distance between the innermost aspect and outermost aspect of the smooth muscle was measured at 3 different positions
around each airway, using NIH Image J software. Data is represented as airway smooth muscle thickness in μm ± SEM. * p < 0.01. An average of
30 airways was used for each group.
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Page 12 of 18IL-18 and IL-33 [52]. These cytokines play important
roles in initiation and amplification of TH2r e s p o n s e s
including TH2 cell proliferation and eosinophilia [52,53].
Alum also induces production of IL-4 and IL-5 in T cells
[54].
Eosinophil migration and recruitment into the lungs
depend on several factors. IL-5 controls differentiation,
activation and survival of eosinophils in the bone marrow
and is essential for their mobilization into the lungs
(reviewed in [36,55]). Eosinophil migration into the lung is
mediated by adhesion to the vascular endothelium via
VCAM-1 [56]. Chemokines produced by airway epithelial
cells and macrophages recruit eosinophils into the airways
[36]. Eotaxin-1 (CCL11) and Eotaxin-2 (CCL24) are eosi-
nophil chemoattractive proteins, mainly produced by air-
way epithelial cells [36] upon IL-4 or IL-13 stimulation
[37,38]. This was further substantiated by Munitz et. al.
when they demonstrated that eotaxin secretion in mice is
completely dependent on the IL-13Ra1 chain and thus the
Type II IL-4/IL-13 receptor (the only receptor expressed
on epithelial cells). In our studies, we show that eotaxin
secretion in the BAL is markedly reduced in the absence
of STAT6 or IL-4Ra. This might explain the lower levels
of eosinophils seen around the airways and blood vessels
in STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice in compari-
son to RAG2
-/- mice. However, in absence of eotaxin, IL-5
may play a major role in recruitment of eosinophils in
STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice. The higher
levels of IL-5 found in the BAL in these mice points to
this direction. Other chemokines such as RANTES, Mono-
cyte Chemoattractant Proteins (MCP) or Macrophage
Inflammatory Protein (MIP)-1a could also play a role in
this process. Interestingly, we found that greater numbers
of eosinophils were present in the lung parenchyma in
mice deficient in STAT6 and IL-4Ra. It is possible that in
absence of eotaxin, eosinophils are unable to reach the air-
w a y sa n dr e m a i ni nt h ep a r e n c h y m a .
In previous studies using WT and STAT6
-/- mice, TH2
cytokine production was higher in WT mice in compari-
son to mice lacking STAT6 [1]. This is because STAT6 is
required for TH2 cell differentiation. Since we provided
WT effector T cells to all the groups of mice, they were
capable of producing TH2 cytokines. When we measured
the amounts of IL-4 and IL-13 in the BAL in allergen chal-
lenged mice, we found that significantly higher amounts of
these cytokines were present in IL-4RaxRAG2
-/- mice
than RAG2
-/- and STAT6xRAG2
-/- mice. Studies have
shown that binding of IL-4 to the IL-4R complex induces
internalization and uptake of this cytokine [39], analogous
to that observed with binding of IL-2 to the IL2R complex
[57,58]. Moreover, other groups have found that IL-4 con-
centration in the BAL was significantly increased when
antibodies against the IL-4Ra chain were injected into
mice, compared to control mice [40]. Similarly, more IL-
13 was found in the BAL in IL-13Ra1
-/- mice [34]. There-
fore, based on our findings and published literature we
hypothesize that the absence of IL-4Ra on cell surfaces
may be preventing the internalization of IL-4 and IL-13,
thus increasing the concentration of these cytokines in the
BAL in IL-4RaxRAG2
-/- mice.
Our data also demonstrated that more IL-5 was secreted
into the BAL when mice lacked STAT6 or the IL-4Ra
chain. The higher concentration of IL-5 found in STAT6x-
RAG2
-/- mice in this model are consistent with the results
reported by Mathew et. al. [6]. They had observed that
when in vitro generated TH2 effectors were adoptively
transferred into STAT6
-/- mice, there was a dramatic
increase in IL-5 secretion in the BAL [6]. The authors
speculated that this difference was due to decreased con-
sumption of IL-5 by eosinophils. In our model, since the
STAT6xRAG2
-/- and IL-4RaxRAG2
-/-mice have signifi-
cantly lower levels of eosinophils in both the BAL and
lung tissue (Figure 3 and additional file 2, Figure S2), it is
possible that the enhanced cytokine level in the BAL in
these mice is due to reduced consumption. We did not
see any significant differences in IFNg levels in the three
strains of mice. IL-17 is another cytokine that has been
implicated in asthma in humans and mice (reviewed in
[59]). In our asthma model, IL-17 levels in the BAL were
below detection limits in all 3 mouse groups.
As our understanding of the roles of IL-4 and IL-13
increases, it is becoming clear that in addition to their
action on T cells, B cells, eosinophils, epithelial cells, these
cytokines can also stimulate macrophages such that they
become alternatively activated. Instead of expressing iNOS
like the classically activated macrophages, these cells pro-
duce proteins such as Arginase, FIZZ and YM1/2 among
others (reviewed in [19,20]). It has now been established
that IL-4 and IL-13 can also induce expression of the
same group of proteins in airway and alveolar epithelial
cells. As mentioned earlier, copious amounts of FIZZ1 and
YM1 have been detected in the BAL of allergen challenged
mice [21]. In addition, upregulated levels of FIZZ1 and
YM1 mRNA have also been found in parasite infection
models [20], allergic lung inflammation and allergic perito-
nitis [21,23,24], bleomycin-induced lung fibrosis [25] and
hypoxia-induced pulmonary hypertension [60]. Stutz et.
al. [23] demonstrated using the BMnot cell line that the
FIZZ1 promoter contains functional binding sites for
STAT6 and C/EBP. They further showed that STAT6 and
C/EBP cooperated together to get optimal FIZZ1 expres-
sion. Welch et. al. [24] showed similar results for the YM1
promoter region using epithelial and macrophage cell
lines: YM1 has several STAT6 binding sites in its promo-
ter region. Additional studies have indicated that induction
of FIZZ1 or YM1 transcripts are STAT6 dependent in
bleomycin-induced lung fibrosis and allergic peritonitis
model systems respectively [24,25].
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expression is induced upon allergen challenge in RAG2
-/-
mice. We demonstrate for the first time in an allergic lung
inflammation model that expression of these AAM pro-
teins is completely dependent on signaling through IL-
4Ra and STAT6. Furthermore, epithelial cells in control
mice expressed both FIZZ1 and YM1 but macrophages
expressed only YM1. This was surprising to us since we
have shown previously that IL-4 induces a robust increase
in FIZZ1 transcript levels in bone marrow macrophages
(BMMs) within the first 6 hours of stimulation [27]. We
failed to see FIZZ1 protein even when macrophages were
stimulated with IL-4 in vitro for 48 hours. However,
macrophages infected with nematodes or Francisella
tularensis have been reported to express FIZZ1 protein
[61]. The absence of this protein in macrophages in our
studies could be due to decreased mRNA stability or post-
translational modification of the FIZZ1 mRNA, leading to
its degradation. More studies are required to elucidate the
molecular basis of this finding.
The functions of the AAM proteins in allergic lung
inflammation and other diseases are still under debate and
may differ depending on the disease setting and signaling
pathways involved. FIZZ1 has been shown to have a pro-
tective effect in parasite infection studies. Two groups
have shown independently that FIZZ1
-/- mice display sig-
nificantly higher inflammation in the lung and liver, char-
acterized by increased granuloma formation and extensive
fibrosis when infected with Schistosoma mansoni or Nip-
postrongylus brasiliensis [20,22]. It was demonstrated that
FIZZ1 is required for worm expulsion and also for sup-
pressing excessive TH2 inflammation. On the other hand,
FIZZ1 has been implicated in exacerbating pulmonary
inflammation, vascular remodeling, collagen and extracel-
lular matrix deposition leading to fibrosis in hypoxia-
induced pulmonary hypertension and bleomycin-induced
lung fibrosis models [26,43]. YM1 which is a secreted chit-
inase-like lectin binds to chitin but does not degrade it. It
is postulated that YM1 is involved in worm egg degrada-
tion and tissue repair [62] and may also be involved in tis-
sue remodeling [44]. More importantly, YM1 can act as an
eosinophil chemoattractant [63,64].
The reduced expression of FIZZ1 and YM1 in the
absence of STAT6 or IL-4Ra may be functionally linked
to the reduced inflammation and eosinophilia seen in
STAT6xRAG2
-/- and IL-4RaxRAG2
-/- mice. Moreover, we
f o u n dt h a tt h e r ew a sas i g n i f i c a n td e c r e a s ei nc o l l a g e n
deposition and airway smooth muscle thickness in mice
lacking STAT6 and IL-4Ra. Enhanced inflammation and
eosinophilia as well as AAM products can contribute to
airway remodeling. Studies have shown that depletion of
the eosinophil lineage protected both humans and mice
from deposition of collagen, extracellular matrix proteins
and increases in smooth muscle mass [41,42,65,66]. It was
recently shown that another chitinase-like protein BRP-39,
was highly upregulated in alveolar macrophages and
epithelial cells upon OVA sensitization and challenge [67].
In the absence of BRP39 there were reduced antigen-spe-
cific TH2 responses including IL-13 induced tissue inflam-
mation and fibrosis. Based on these data and our earlier
finding that IL-4 dramatically increases AAM gene expres-
sion in macrophages [27], we are inclined to think that
elevated expression of AAM proteins including FIZZ1 and
YM1 increases the severity of lung pathology.
Conclusions
In summary, our data demonstrates that in vivo primed
CD4+ T cells are able to support allergic lung inflamma-
tion. Moreover, STAT6 and IL-4Ra play a major role in a
range of TH2 responses but the extent to which these sig-
naling proteins control various aspects of allergic lung dis-
ease is variable. Our study establishes that STAT6 and IL-
4Ra are necessary for FIZZ1 and YM1 protein induction
but are only partially responsible for the recruitment of
eosinophils and pulmonary inflammation. Further research
is required to tease out the other pathways that are contri-
buting to the severity of allergic lung inflammation.
Methods
Mice
Mice deficient in RAG2 (RAG2
-/-)o naB A L B / cb a c k -
ground and DO11.10xRAG2
-/- transgenic mice containing
T Cell Receptors (TCRs) specific for OVA peptide 323-
339, were purchased from Taconic (Germantown, NY) or
bred in the animal care facility at the University of Mary-
land, Baltimore (UMB). STAT6xRAG2
-/- mice were gener-
ated by crossing STAT6
-/- mice and RAG2
-/- mice [18].
The IL-4RaxRAG2
-/- mice were bred at Taconic under
contract and then maintained at UMB. Both the STAT6x-
RAG2
-/- and IL-4RaxRAG2
-/- mice were on a BALB/c
background. All experimental procedures mentioned here
were performed in accordance to the guidelines issued by
the Institutional Animal Care and Use Committee at the
University of Maryland, Baltimore.
Generation and adoptive transfer of naïve or in vivo
primed CD4 T cells
DO11.10xRAG2
-/- mice were either used directly or
immunized with 100 μg of chicken egg ovalbumin (OVA;
Sigma-Aldrich, St. Louis, MO) adsorbed to aluminum
hydroxide (alum; Sigma-Aldrich, St. Louis, MO) intraperi-
toneally (i.p). LN cells and splenocytes were harvested 10
days later to isolate naïve or in vivo primed T cells. These
cells were treated with CD4 T cell negative selection
enrichment cocktail and CD4+ T cells were purified either
by using column separation (R&D Systems, Minneapolis,
MN) or column-free immunomagnetic separation (Stem
Cell Technologies, Vancouver, Canada). These cells were
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injected intravenously (i.v.) via the tail vein in recipient
mice (5 × 10
6 cells/mouse).
In vivo proliferation assay and measurement of T cell
activation
RAG2
-/- mice were adoptively transferred with ~2 × 10
6
naïve or in vivo primed CD4+ T cells from DO11.10x-
RAG2
-/- mice on day 0 and immunized with OVA/alum
on day 1. Mice were treated daily with BrdU diluted in
PBS (1 mg/mouse) i.p for 3 days. Splenocytes were isolated
from two mice each for the naïve or in vivo primed
groups, pooled together and stained with antibodies for
CD4, KJ126, CD44 and BrdU. The cells were then ana-
lyzed by flow cytometry. A BrdU staining kit (BD Bios-
ciences, San Jose, CA) was used for intracellular staining
for BrdU. Another group of 4 mice that didn’tr e c e i v e
BrdU, were immunized with OVA/alum a second time on
day 8. 4 days later, splenocytes were harvested on day 12,
counted and stimulated with PMA (50 ng/ml) and Iono-
mycin (1 μg/ml) for 6 h in the presence of Brefeldin A.
CD44 expression and IL-4 production was monitored
using flow cytometry.
Antigen sensitization and challenge
Mice were sensitized and challenged with chicken egg
ovalbumin using a modified protocol described by Wang
et al. [68]. Each mouse was immunized with either 100 μg
of OVA/alum or alum alone on day 1 and again on day 6.
After the last sensitization step, mice were challenged with
aerosolized PBS or 1% OVA in PBS for 40 minutes each
day on days 12 and 14.
Evaluation of airway inflammation
Mice were anaesthetized 48 hours after the last OVA chal-
lenge. Bronchial lavage was performed on each mouse by
inserting a 1 mm tube into the trachea and flushing the
lungs with 1 ml of PBS. The samples were centrifuged and
the supernatant was used for cytokine analysis. The cellu-
lar component of the bronchoalveolar lavage (BAL) was
resuspended in PBS. Total cell counts were determined.
Cytospin preparations of the cells were stained with Diff-
Quick (Dade Behring, Newark, DE) and differential cell
counts were performed based on light microscopic
analysis.
Lung histology and Immunohistochemistry
Lung histology sections were prepared as described [7].
Briefly, mouse heart and lungs were perfused with 10-15
ml of PBS to remove red blood cells. Lung samples were
immediately fixed with 10% formalin for 2 hours at room
temperature and stored in 70% ethanol. The tissues were
then processed, embedded in paraffin and sectioned.
Next, the slides were deparaffinized and stained with
Hematoxylin and Eosin (H&E) or Periodic acid Schiff
(PAS). Immunohistochemistry: After deparaffinization,
slides were washed with PBS and immersed in a solution
of methanol and 0.3% H2O2 for 30 minutes to deplete
endogenous peroxidase activity. Slides were stained with
1:100 dilution of rat anti-CD3 (Serotec, Raleigh, NC) fol-
lowed by 1:200 dilution of biotinylated anti-rat mouse
adsorbed antibodies (Vector Laboratories Inc. Burlin-
game, CA). For FIZZ1 and YM1 staining, sections were
incubated first with 10% goat serum for 20 minutes, then
stained with a 1:100 dilution of rabbit anti-mouse FIZZ1
(Abcam, Cambridge, MA) or 1:100 dilution of rabbit
anti-mouse YM1 (Stem Cell Technologies, Vancouver,
Canada) followed by biotinylated anti-rabbit antibodies
(1:200; Vector Laboratories Inc.). Finally, all slides were
incubated with ABC Elite reagent (Vector Laboratories),
developed in 3,3-diaminobenzidine chromogen and
counterstained with Mayer’s Hematoxylin.
Assessment of Airway Remodeling
Paraffin embedded lung sections were stained with Mas-
son’s Trichrome stain to visualize collagen deposition
(blue). Keratin and muscle fibers appear red. To quantify
collagen, photomicrographs of Masson’s Trichrome
stained lung sections (10× and 100× magnification) were
obtained and evaluated using NIH Image J image analysis
software [46] (National Institutes of Health, Bethesda,
MD). Twenty airways/blood vessels were analyzed from
each group of mice. Airway smooth muscle thickness was
measured using H&E stained lung sections as described
in [45]. Briefly, photomicrographs of 100× magnification
H&E stained lung sections were taken. The thickness of
the airway smooth muscle layer (transverse section) from
t h ei n n e r m o s ta s p e c tt ot h eo u t e r m o s ta s p e c tw a sm e a -
sured at 3 different positions around each airway, using
NIH Image J software. An average of 30 airways was used
for each group.
Western blot and densitometry analysis
Total protein present in BAL fluid samples isolated from
mice was quantified using a micro BCA protein assay kit
(Pierce, Rockford, IL). Equal amounts of total BAL pro-
tein was run on a 10% or 18% polyacrylamide gel and
transferred onto an Immobilon membrane (Millipore,
Billerica, MA). The blots were blocked and incubated
with antibodies for YM1 (StemCell Technologies) or
FIZZ1 (Alpha Diagnostic International Inc., San Antonio,
Texas). An anti-rabbit horse radish peroxidase-linked
secondary antibody was used (GE Healthcare). Protein
bands were detected using a chemiluminescence reagent
(ECL; Denville Scientific Inc., Metuchen, NJ). For densi-
tometry analysis, shorter exposure films were scanned
and the density of each band was analyzed with the NIH
Image software.
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Cytokines and chemokines in the BAL fluid were analyzed
by using the SearchLight Multiplex array system (Pierce
Thermo Scientific; now sold by Aushon Biosystems). IL-4
and IL-5 secretion by splenocytes from naïve or OVA/
Alum immunized D011.10xRAG2
-/- mice were measured
using kits (Pierce Thermo Scientific, Rockford, IL; R&D
Systems, Minneapolis, MN) as mentioned in [69]. Briefly,
splenocytes were isolated from mice mentioned above and
cultured in complete RPMI medium supplemented with
20 U/ml of IL-2 (R&D Systems, Minneapolis, MN) in the
presence or absence of PMA (20 ng/ml) (Sigma-Aldrich,
St. Louis, MO) and Ionomycin (1 μg/ml) (Sigma-Aldrich)
for 18 h. Cell culture supernatants were used to measure
cytokine levels.
FACS analysis
Single cell suspensions of splenocytes were stained with
fluorochrome conjugated antibodies and analyzed by flow
cytometry using a FACS Calibur machine (Becton Dickin-
son, Franklin Lakes, NJ). The following antibodies were
used for cell surface staining: anti-CD4-PE (clone GK1.5;
BD Biosciences), anti-CD4-Alexa Fluor 647 (clone RM4-5;
BD Biosciences), anti-DO11.10 TCR-FITC (clone KJ126;
eBioscience) and anti-CD44-PerCP Cy5.5 (clone IM7;
eBioscience). Intra-cellular cytokine staining was per-
formed to detect IL-4 production. Cells were fixed and
permeabilized, followed by staining with anti-IL-4-PE
(clone BVD4; BD Biosciences). Data was analyzed by using
FlowJo software (Treestar, CostaMesa, CA).
Statistical Analysis
Student two-tailed t test was used to compare the differ-
ences between two groups and to calculate the significance
values. P values of ≤ 0.05 were considered statistically
significant.
Additional material
Additional file 1: Figure S1: Lung inflammation in response to
allergen priming and challenge in RAG2
-/- and STAT6 or IL-4Ra
deficient mice. In vivo primed DO11.10+ CD4+ T cells were adoptively
transferred into RAG2
-/-, STAT6xRAG2
-/- or IL-4RaxRAG2
-/- mice. Mice were
primed with 100 μg of Ova in alum i.p on d. 1 & 6 and then challenged
with 1% Ova in PBS on d. 12 &14. Mice were sacrificed, BAL and lung
tissue was collected 48 h after the last challenge. (A) Percentages of
eosinophils present in the BAL in alum or OVA/alum treated mice are
shown. (B) H&E (panels a, d & g- 10X; panels b, e & h- 100X) and PAS
(panels c, f & i- 10X) stained lung sections of mice mentioned above.
Arrows point areas of inflammation. Data is representative of three
independent experiments.
Additional file 2: Figure S2: Absence of STAT6 and IL-4Ra causes
reduced eosinophil accumulation in the lung. Lung sections of Ova
primed and challenged mice mentioned in Figure S1 were stained with
H&E. Eosinophils and mononuclear cells in each lung section was
counted and graphed. Number of cells around the airways (A), blood
vessels (B) and in the lung parenchyma (C) are shown. White bars
represent eosinophils, black bars represent mononuclear cells. Data
represented as cell counts ± SEM. HPF: high power field; 100X. * p <
0.05; + p < 0.01; ** p < 0.0001. # (p < 0.001) represents statistically
significant differences when compared to the RAG2KO group. n = 5 for
each mouse strain.
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